QXL138AM / Nammi Therap - LARVOL DELTA

Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma (PRNewswire) - "Nammi Therapeutics, Inc...announces dosing of the first patient in the first in human Phase 1 trial...The Company will conduct the Phase 1 study at investigator sites across the United States."

Trial status • Multiple Myeloma • Oncology • Solid Tumor

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Nammi Therapeutics Inc

Metastases • New P1 trial • Breast Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Genito-urinary Cancer • Hematological Malignancies • Hepatocellular Cancer • Hepatology • Lung Cancer • Multiple Myeloma • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • IL2 • IL6 • TNFA

Nammi Therapeutics, Inc. Completes Series B Round with Investment from MMRF's Myeloma Investment Fund; Advances Clinical Development of Lead Program, QXL138AM (PRNewswire) - "Nammi Therapeutics...announces a $1M investment commitment by the Myeloma Investment Fund (MIF) in a $30M Series B financing round prior to the planned start of a first-in-human Phase 1 study of our lead program, QXL138AM, in patients with locally advanced unresectable and/or metastatic solid tumors and multiple myeloma. QXL138AM is a Masked Immunocytokine (MIC) comprised of a masked interferon alpha (IFNa) fused to an antibody that targets the CD138 protein on the surface of the tumor cells....Preclinical data has demonstrated significant anti-tumor efficacy across more than 10 tumor types including multiple myeloma where complete regression at doses as low as 0.1 mg/kg have been observed. Nammi has secured Orphan Drug Designation in multiple myeloma from the FDA on the strength of this data."

Financing • Orphan drug • Preclinical • Multiple Myeloma • Solid Tumor

A targeted masked ImmunoCytokine for CD138 expressing cancers (SITC 2023) - "QXL138AM is a masked immunocytokine comprised of an anti-CD138 antibody fused to a masked IFNα2a via a cleavable linker...Finally, the peptide mask slightly altered its efficacy in a human xenograft tumor model compared to an analogous control lacking the mask. Together these data suggested that tumor targeting of IFNA, combined with selective mask removal in the tumor environment could maximize potency while minimizing IFNA receptor activation in normal tissues."

Oncology • IFNA1 • SDC1 • ST14

"#NammiTherapeutics Granted #FDA #OrphanDrug Designation For #QXL138AM for the Treatment of #MultipleMyeloma https://t.co/Bzi6fPr4pj" (@1stOncology)

FDA event • Orphan drug • Hematological Malignancies • Multiple Myeloma • Oncology

Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Pancreatic Cancer (PRNewswire) - "Nammi Therapeutics, Inc...announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead program, QXL138AM, for the treatment of Pancreatic Cancer. Nammi has previously received ODD for QXL138AM for treatment of multiple myeloma."

Orphan drug • Gastrointestinal Cancer • Oncology • Pancreatic Cancer

Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Multiple Myeloma (PRNewswire) - "Nammi Therapeutics, Inc...announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead program, QXL138AM, for the treatment of multiple myeloma."

Orphan drug • Hematological Malignancies • Multiple Myeloma • Oncology

Nammi Therapeutics Unveils Two Novel Immunotherapies at AACR Conference (PRNewswire) - "QXL138AM: Poster #1726 highlights preclinical validation of our first in class MIC comprised of a CD138-targeted antibody fused with Interferon alpha (IFNα) that is masked with a tumor-selectively releasable peptide....NTI-55: Poster #1581 highlights preclinical validation of NTI-55, a novel combination of validated immune modulator lipid prodrugs, including a TLR7 agonist and an A2AR inhibitor, that stimulates an immune response and blocks an important tumor-derived immune checkpoint."

Preclinical • Oncology